Muhammad O Chohan1, Christopher T Ryan2, Ranjodh Singh2, Ryan M Lanning3, Anne S Reiner4, Marc K Rosenblum5, Viviane Tabar1, Philip H Gutin1. 1. Department of Neurosurgery, Memorial Sloan-Kettering Cancer Center, New York, New York. 2. Department of Neurosurgery, Weill Medical College of Cornell University, New York, New York. 3. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York. 4. Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York. 5. Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York.
Abstract
BACKGROUND: Recurrence rates for atypical and anaplastic meningiomas range between 9% and 50% after gross total resection and between 36% and 83% after subtotal resection. Optimal treatment of recurrent meningiomas exhibiting atypical/anaplastic histology is complicated because they are often refractory to both surgery and radiation. OBJECTIVE: To evaluate clinical determinants of recurrence and treatment-specific outcomes in patients with recurrent meningiomas exhibiting atypical/anaplastic histology at our institution. METHODS: A cohort study was conducted using clinical data of all patients treated for meningiomas with atypical/anaplastic histology at first recurrence between January 1985 and July 2014 at a tertiary cancer center. Predictors of second recurrence were analyzed using competing risks regression models. RESULTS: Nine hundred eighteen patients with meningioma were screened, of whom 60 (55% female) had recurrent disease with atypical/anaplastic histology at a median age of 58.1 yr at diagnosis. The median follow-up from the time of first recurrence was 36.7 mo, with 32 (53%) patients alive at last follow-up. There was no effect of extent of resection at first recurrence on time to a subsequent recurrence. Inclusion of radiation as primary or adjuvant therapy at first recurrence reduced the risk of progression or subsequent recurrence compared to surgery alone (P = .07). CONCLUSION: Treatment of recurrent meningiomas with atypical/anaplastic histology remains challenging. Our data, from one of the largest cohorts, suggest better tumor control with the addition of radiation and challenges the importance of extent of resection at first recurrence. A multicenter effort is needed to confirm these findings and propose treatment guidelines.
BACKGROUND: Recurrence rates for atypical and anaplastic meningiomas range between 9% and 50% after gross total resection and between 36% and 83% after subtotal resection. Optimal treatment of recurrent meningiomas exhibiting atypical/anaplastic histology is complicated because they are often refractory to both surgery and radiation. OBJECTIVE: To evaluate clinical determinants of recurrence and treatment-specific outcomes in patients with recurrent meningiomas exhibiting atypical/anaplastic histology at our institution. METHODS: A cohort study was conducted using clinical data of all patients treated for meningiomas with atypical/anaplastic histology at first recurrence between January 1985 and July 2014 at a tertiary cancer center. Predictors of second recurrence were analyzed using competing risks regression models. RESULTS: Nine hundred eighteen patients with meningioma were screened, of whom 60 (55% female) had recurrent disease with atypical/anaplastic histology at a median age of 58.1 yr at diagnosis. The median follow-up from the time of first recurrence was 36.7 mo, with 32 (53%) patients alive at last follow-up. There was no effect of extent of resection at first recurrence on time to a subsequent recurrence. Inclusion of radiation as primary or adjuvant therapy at first recurrence reduced the risk of progression or subsequent recurrence compared to surgery alone (P = .07). CONCLUSION: Treatment of recurrent meningiomas with atypical/anaplastic histology remains challenging. Our data, from one of the largest cohorts, suggest better tumor control with the addition of radiation and challenges the importance of extent of resection at first recurrence. A multicenter effort is needed to confirm these findings and propose treatment guidelines.
Authors: Clara Y H Choi; Scott G Soltys; Iris C Gibbs; Griffith R Harsh; Paul S Jackson; Robert E Lieberson; Steven D Chang; John R Adler Journal: Neurosurgery Date: 2010-11 Impact factor: 4.654
Authors: W Hoffmann; H Mühleisen; C F Hess; R D Kortmann; B Schmidt; E H Grote; M Bamberg Journal: Acta Neurochir (Wien) Date: 1995 Impact factor: 2.216
Authors: E B Hug; A Devries; A F Thornton; J E Munzenride; F S Pardo; E T Hedley-Whyte; M R Bussiere; R Ojemann Journal: J Neurooncol Date: 2000-06 Impact factor: 4.130
Authors: Manish K Aghi; Bob S Carter; Garth R Cosgrove; Robert G Ojemann; Sepideh Amin-Hanjani; Robert L Martuza; William T Curry; Fred G Barker Journal: Neurosurgery Date: 2009-01 Impact factor: 4.654
Authors: Ricardo J Komotar; J Bryan Iorgulescu; Daniel M S Raper; Eric C Holland; Kathryn Beal; Mark H Bilsky; Cameron W Brennan; Viviane Tabar; Jonathan H Sherman; Yoshiya Yamada; Philip H Gutin Journal: J Neurosurg Date: 2012-08-24 Impact factor: 5.115
Authors: Michael A Mooney; Wenya Linda Bi; Jonathan M Cantalino; Kyle C Wu; Thomas C Harris; Lucas L Possatti; Parikshit Juvekar; Liangge Hsu; Ian F Dunn; Ossama Al-Mefty; Phillip M Devlin Journal: J Neurooncol Date: 2019-11-19 Impact factor: 4.130
Authors: Bhuvic Patel; Rupen Desai; Sangami Pugazenthi; Omar H Butt; Jiayi Huang; Albert H Kim Journal: Front Oncol Date: 2022-03-23 Impact factor: 6.244
Authors: Karol P Budohoski; James Clerkin; Christopher P Millward; Philip J O'Halloran; Mueez Waqar; Seamus Looby; Adam M H Young; Mathew R Guilfoyle; Diana Fitzroll; Abel Devadass; Kieren Allinson; Michael Farrell; Mohsen Javadpour; Michael D Jenkinson; Thomas Santarius; Ramez W Kirollos Journal: Acta Neurochir (Wien) Date: 2018-06-30 Impact factor: 2.216
Authors: Hongda Zhu; Wenya Linda Bi; Ayal Aizer; Lingyang Hua; Mi Tian; Jiaojiao Den; Hailiang Tang; Hong Chen; Yin Wang; Ying Mao; Ian F Dunn; Qing Xie; Ye Gong Journal: Cancer Med Date: 2019-01 Impact factor: 4.452